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Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide and is an emerging global
epidemic. It is characterized by an imbalance between production and clearance of amyloid b (Ab) and tau
proteins. Oligomeric forms of Ab and tau are believed to be the most toxic. Dramatic results from AD animal
models showed great promise for active and passive immune therapies targeting Ab. However, there is very
limited evidence in human studies of the clinical benefits from these approaches. Immunotherapies targeting
only tau pathology have had some success but are limited so far to mouse models. The majority of current
methods is based on immunological targeting of a self-protein; hence, benefits need to be balanced against
risks of stimulating excessive autoimmune toxic inflammation. For greater efficacy the next generation of
vaccines needs to focus more on concurrently targeting all the intermediate toxic conformers of oligomeric
Ab and tau species.Alzheimer’s disease (AD) affects more than 20 million people
worldwide currently, with about 135 million people expected
to develop it by 2050. The staggering numbers affected by
this global health epidemic translates into significant direct
and indirect health care expenses, with direct costs for the
USA alone estimated to be about $214 billion in 2014. Histori-
cally, AD has been characterized as a neurodegenerative dis-
ease chiefly defined by its pathological signature including b
amyloid deposits in the form of extracellular amyloid b (Ab)
plaques and tau protein aggregates in the form of intracellular
neurofibrillary tangles (NFTs) (Nelson et al., 2012). A central
mechanism underlying the formation of both amyloid plaques
and NFTs in AD is pathogenic cerebral protein aggregation.
Though both amyloid plaques and aggregated tau have an
essential role in AD pathology and are part of the neuropatho-
logical definition of the disease, numerous studies suggest that
in these precipitated forms they are relatively biologically inert.
Hence, the accumulation of aggregated Ab in plaques corre-
lates poorly with the clinical status of patients (Nelson et al.,
2012; Terry, 1996).
Soluble oligomeric forms of Ab and tau, which may replicate
via a ‘‘prion-like’’ mechanism, are thought to be the chief medi-
ators of cytotoxicity in AD (Ashe and Aguzzi, 2013). These oligo-
meric species of Ab initially accumulate intraneuronally, eventu-
ally leading to cell death and the extracellular deposition of
amyloid plaques (D’Andrea et al., 2001; Gouras et al., 2000).
Both Ab and tau oligomers have similar but not identical struc-
tural and biophysical properties, including a high b sheet con-
tent, some resistance to proteolytic degradation, and neuronal
toxicity. Recent work also has revealed that Ab- and tau-related
pathology can, in certain scenarios, ‘‘seed’’ or transmit each
other (Ashe and Aguzzi, 2013; Jucker andWalker, 2011). Existing
therapies have either no or minimal disease-modifying benefit.1162 Neuron 85, March 18, 2015 ª2015 Elsevier Inc.Hence, a number of novel therapeutic strategies are currently un-
der investigation, many of which involve modulating the immune
system.
Preclinical studies in transgenic mouse models have shown
great efficacy of immunotherapy in the prevention of both AD
and prion diseases (Wisniewski and Gon˜i, 2012; Wisniewski
and Gon˜i, 2014). With a central role for Ab in AD pathogenesis
under the ‘‘amyloid cascade’’ model, several strategies directed
toward the eradication of Ab and downstream targets via small
molecules or immunotherapies have been and are being ex-
plored (Huang and Mucke, 2012; Morgan, 2011; Ozudogru and
Lippa, 2012; Wisniewski and Gon˜i, 2014). Though Ab-directed
immunization via multiple approaches has shown promising re-
sults in AD Tg mouse models, the translation to safe and effica-
cious therapy for humans still remains a challenge. Insights from
these studies have raised further issues that need to be ad-
dressed in current and future studies. Questions that have
arisen from previous work, which are critical for the development
of successful immunotherapy, include identification of the ideal
target and the timing of therapy. What is the best design for a
vaccine that is both specific and safe? How could we avoid auto-
immune toxicity? Would the ideal approach be active or passive
immunization? Is stimulation of the innate immune system a
viable option? Can a single vaccine be designed to target both
Ab- and tau-related pathology simultaneously? This article re-
views current preclinical and clinical data for Ab and phosphor-
ylated tau reduction immunotherapy and discusses how this
information may lead to the next generation of more effective
vaccines.
Pathogenesis of Alzheimer’s Disease
AD is a complex neurodegenerative disease characterized clini-
cally by a progressive deterioration of memory. Pathologically it
Figure 1. Ab and Tau Conformational Changes in AD
(1–5) (1) APP undergoes normal cleavage by b and g-secretase (PS is part of the g-secretase complex) to produce the (2) normal sAb. sAb can undergo a
conformational change to (3) a b sheet-rich conformer that further aggregates to form (4) soluble, toxic Ab oligomers. These also may precipitate to form (5)
relatively inert fibrils in amyloid plaques and congophilic amyloid angiopathy.
(A–F) (A) Tau is a microtubule-binding protein. Tau can undergo (B) hyperphosphorylation or (C) a conformational change to a b sheet conformer. These species
can both further change to (D) hyperphosphorylated tau in a b sheet-rich form that is predisposed to further aggregation into (E) toxic, tau oligomers. These can
precipitate to form (F) PHFs in the form of NFTs.
(I and II) The Ab b sheet conformers and Ab oligomers may cross-seed, under some circumstances, with intermediate tau species in a b sheet conformation and
with tau oligomers, to synergistically exacerbate AD pathology.
The most effective immunotherapeutic approaches for AD will need to be able to concurrently reduce levels of the toxic Ab and tau oligomeric species.
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plaques and congophilic angiopathy (CAA), as well as intracel-
lular hyperphosphorylated fibrillar tau accumulation in the form
of NFTs (Figure 1). Genetic studies have shown that AD is a het-
erogeneous disorder that includes the early-onset (EOAD) form
(<5% of all AD patients with onset at <65 years) and the much
more common sporadic late-onset (LOAD) form (onset at >65
years). EOAD is related to mutations in presenilin 1 (PS1), prese-
nilin 2 (PS2), or the amyloid precursor protein (APP), when asso-
ciated with autosomal dominant inheritance (Bertram and Tanzi,
2012; Guerreiro and Hardy, 2014; Karch et al., 2014). Epidemio-
logical data suggest that apparent autosomal dominant trans-
mission is found in only 10% of all EOAD cases (<1% of all
AD cases), leaving the genetic association of the majority of
EOAD unexplained (Guerreiro and Hardy, 2014; Wingo et al.,
2012).
LOAD afflicts >95% of patients with AD and is related to both
genetic and environmental factors (Bertram and Tanzi, 2012;
Guerreiro and Hardy, 2014; Karch et al., 2014; Kim et al.,2014). Some of the known environmental risk factors for LOAD
include level of physical activity, educational status, diabetes
mellitus, hypertension, and head injury (Beydoun et al., 2014;
Di Marco et al., 2014). The strongest identified genetic risk factor
for LOAD is the inheritance of the apolipoprotein (apo) E4 allele
(Kanekiyo et al., 2014; Potter and Wisniewski, 2012). The role
of apoE in AD is complex but includes isotype-specific effects
on the aggregation and clearance of brain Ab (Kanekiyo et al.,
2014). Recently, rare variants of another gene that encodes
the triggering receptor expressed on myeloid cells 2 (TREM2,
located on 6p21.1) have been reported as a significant risk factor
for LOAD, with an odds ratio similar to apoE4 (Boutajangout and
Wisniewski, 2013; Hickman and El Khoury, 2014). Several hy-
potheses have been postulated for the development of plaques
and tangles, which lead to synaptic and neuronal loss and sub-
sequent decline of memory and cognition in AD.
The most favored theory currently in the field that has served
as the platform for many therapeutic strategies is the amyloid
cascade hypothesis (Hardy and Selkoe, 2002; Holtzman et al.,Neuron 85, March 18, 2015 ª2015 Elsevier Inc. 1163
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gregation, especially in its toxic oligomeric form, is the principal
insult that produces neuronal toxicity and triggers downstream
signaling events that in turn lead to the hyperphosphorylation
of tau and development of NFTs (Figure 1). A multitude of ‘‘chap-
erone’’ proteins have been described that stabilize pathological
oligomers and mediate a conformational change of soluble Ab
(sAb). These include but are not limited to apoE, especially its
E4 isoform; f1-antichymotrypsin (ACT); and C1q complement
factor (Potter and Wisniewski, 2012). Histological and biochem-
ical evidence suggests that ‘‘pathological chaperone’’ proteins
co-localize with fibrillar Ab deposits, but not with preamyloid ag-
gregates that are not linked to neuronal loss. From a biochemical
perspective, a seminal event in the development of pathologic
aggregates is the point at which a critical concentration of sAb
and/or chaperone proteins is achieved. A critical concentration
of the precursor proteins would favor a conformational change,
and drive the formation of toxic Ab oligomers and subsequent
activation of downstream signaling cascades. Mechanisms im-
plicated for achieving this in sporadic AD could be a permutation
of impaired clearance of Ab from the brain as a consequence of
aging and/or inflow of serum Ab into the CNS (Holtzman et al.,
2012).
Several studies in familial AD (FAD) patients and in models of
FAD have provided evidence in favor of the amyloid cascade
hypothesis. The first line of evidence comes from functional an-
alyses of APP gene or in the PS1 or 2 genes that are associated
with inherited forms of AD. Mutations in these genes show
concomitant changes in APP processing biased toward over-
production of sAb or the generation of specific species of
sAb (such as Ab1–42) that are more prone to aggregation
(Hardy, 2006). In addition, a rare APP mutation (first reported
in an Icelandic population) that protects against AD is support-
ive of the amyloid cascade (Jonsson et al., 2012). This mutation
(A673T) acts by reducing amyloidogenic processing of APP and
also mildly decreasing Ab peptide aggregation (Maloney et al.,
2014). The next line of evidence stems from the association of
Down’s syndrome with AD-related pathology at a very young
age. Here, an extra copy of the APP gene secondary to trisomy
21 provides excellent in vivo gain-of-function evidence sup-
porting the amyloid hypothesis (Hartley et al., 2014). Further,
animal models where Ab and tau are co-expressed reveal
that Ab deposition predates formation of tau aggregates, sup-
porting the concept that NFT formation is downstream from
Ab aggregation (Go¨tz et al., 2001; Oddo et al., 2003; Wisniew-
ski and Sigurdsson, 2010). Lastly, enhancement of Ab clear-
ance in transgenic mouse models with overexpression of
mutant APP, but with no tau pathology, has been shown to
improve cognitive function in mice (Lemere, 2013; Wisniewski
and Sigurdsson, 2010). Subsequent work also has revealed
that the inhibition of Ab in animal models with overexpression
of mutant APP and tau not only prevents the development of
tau-related aggregates but also improves cognitive deficits
(Blurton-Jones and Laferla, 2006; McKee et al., 2008; Oddo
et al., 2006).
In contrast to the genetic forms of AD where the role of Ab
is well established, definitive evidence regarding Ab’s central
function in sporadic LOAD is more limited. A number of autopsy1164 Neuron 85, March 18, 2015 ª2015 Elsevier Inc.studies have indicated that medial temporal and subcortical tau
pathology precedes Ab pathology in the majority of patients
(Jack et al., 2013). Genome-wide association studies (GWAS)
in LOAD have implicated a number of different genes involved
in innate immunity, cholesterol metabolism, and endocytosis,
suggesting greater etiological heterogeneity (Karch et al.,
2014). Supporting a role of Ab in LOAD, the levels of biochemi-
cally extracted Ab peptides from the brains of people with spo-
radic AD correlate well with cognitive deficits (Na¨slund et al.,
2000). Further, Ab peptide dimer/oligomer extracts derived
from sporadic AD brains have been shown to disrupt synaptic
structure, function, and plasticity, which are critical cellular cor-
relates of memory (Shankar et al., 2008). Interestingly, exoge-
nous injections of Ab extracts from sporadic AD patients can
induce amyloid aggregates in transgenic mice (Ashe and Aguzzi,
2013; Meyer-Luehmann et al., 2006).
One of the significant concerns with the amyloid cascade hy-
pothesis comes from the post-mortem analyses from the active
vaccination trials in humans. (Holmes et al., 2008). Individuals
from the active immunization or the ‘‘test’’ arm revealed a signif-
icant decrease in plaque burden and strikingly reduced Ab load
relative to non-immunized controls. Regardless of these encour-
aging results, no improvements in long-term survival outcome,
time to severe dementia, and cognitive function were seen
among the immunized groups. Two recent, large phase III trials
of passive immunization for AD also have ended with no evi-
dence of clinical benefit, although post hoc analysis suggested
a positive trend in a subpopulation of early AD patients in the Sol-
anezumab trial (Doody et al., 2014; Salloway et al., 2014). One
plausible explanation here is that immunization was conducted
in the late stage of the disease process, possibly out of the win-
dow to translate into a meaningful clinical benefit (Holtzman
et al., 2012; Wisniewski and Gon˜i, 2014).
One also could theorize that the amyloid hypothesis repre-
sents only part of the complete story. The existence of a
currently unknown upstream factor(s) or insult that triggers
both the Ab and tau pathways downstream of itself is also
possible (Castellani et al., 2008; Small and Duff, 2008). We hy-
pothesize that Ab and tau abnormal conformers interact; how-
ever, the importance of individual abnormal conformers to this
interaction and their influence on pathology might differ from
patient to patient (Figure 1). Recent data suggest that, in
many cases, a regionally limited tauopathy precedes Ab pathol-
ogy; however, for the tau pathology to evolve to AD, it requires
the concomitant presence of Ab pathology (Braak and Del Tre-
dici, 2011; Crary et al., 2014; Duyckaerts, 2011; Jack et al.,
2013). Hence tau and Ab may be independent processes that
show pathological synergy in the evolution of AD. Regardless
of the heterogeneous pathogenesis of LOAD, immunotherapy
remains an attractive and potentially effective strategy, if it is
targeted to the common pathways of both Ab- and tau-related
pathology in early stages, as well as in clinically symptomatic
AD. Here, we will review both active and passive immunother-
apeutic approaches along with preclinical and clinical data that
have been used to target both Ab and phosphorylated tau.
From past and current experiences, we will try to foresee
possible pathways to effectively treat AD and related neurode-
generative disorders.
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Preliminary work that suggested a strong role for immuno-
therapy for AD revealed that anti-Ab-targeting antibodies were
capable of preventing Ab peptide fibrillization, disrupting pre-
formed fibrils and, thus, thwarting fibril-dependent neurotoxicity
in in vitro cell-culture-based assays (Solomon et al., 1997). This
initial work motivated further in vivo studies to test the role of
Ab first as an active immunogen and then to assess if it could
prevent pathology in mouse models of Ab-related AD pathology.
The first in vivo immunization trial, reported in a seminal paper by
Schenk et al. (1999) demonstrated that full-length, aggregated
Ab1–42 in conjunction with Freund’s adjuvant could reduce pla-
que load in vivo, which at the time was hypothesized to be the
main culprit in AD pathology (Schenk et al., 1999). No obvious
toxicity was reported in this trial. Results along the same line
were confirmed and extended in later studies, where active im-
munization with Ab1–42 or Ab homologous peptides along with
Freund’s or alum adjuvants not only prevented Ab plaque pathol-
ogy, but also protected against the development of cognitive
deficits (Asuni et al., 2006; Janus et al., 2000; Lemere, 2013;
Morgan et al., 2000; Sigurdsson et al., 2001, 2004).
Biochemical assays identified the first 15 amino acids of the
Ab peptide as the site of the principal epitope. Further, immuno-
histochemical assays also revealed that antibodies generated in
mice toward Ab can label amyloid plaques on human AD brain
sections, raising the possibility of such immune intervention in
humans. Interestingly, peripheral injections of anti-Ab mono-
clonal antibodies (mAbs) into the systemic circulation also could
reduce Ab plaque burden and behavior, suggesting that the ther-
apeutic effect of the vaccine was likely mediated by generating a
humoral response (Bard et al., 2000; DeMattos et al., 2001; Le-
mere, 2013; Wisniewski and Gon˜i, 2014). These pilot preclinical
trials revealed no evidence of toxicity in the immunized mice.
However, there is some debate about the type of immune
response involved in mediating the beneficial effects by these
peptides. Besides the classical view at the time, that fibrillar
Ab with a strong adjuvant was the appropriate immunogen,
another view speculated that the use of non-fibrillogenic, non-
toxic Ab homologous peptides together with adjuvants that acti-
vate primarily the humoral, Th-2 response (rather than the Th-1
cell-mediated response) might be more effective and reduce po-
tential toxicity (Lemere et al., 2001; Sigurdsson et al., 2001, 2002;
Wisniewski and Gon˜i, 2014). The design for the Ab homologous
peptide immunogens, albeit with a few appropriate amino acid
substitutions, is based on the fact that the major B cell epitopes
that are within the first 15 amino acids of Ab form the principal B
cell epitopes, while the mid and carboxyl terminus are the chief
site for the T cell epitopes (Asuni et al., 2006; Sigurdsson et al.,
2001, 2004).
The striking results from these preclinical studies served as the
launching pad for Elan/Wyeth’s group to launch a randomized,
multiple-dose, dose-escalation, double-blind Phase I clinical
trial. This trial, started in April 2000, used the AN1792 vaccine,
which was comprised of pre-aggregated Ab1–42 and QS21 as
an adjuvant. The vaccine was designed to generate a strong
cell-mediated immune response. A strong inducer of Th-1 lym-
phocytes, QS21 produces an effect similar to that obtained in
mice with the use of Freund’s adjuvant, which is not approvedfor use in humans (Wisniewski and Frangione, 2005). The pilot
study performed in the UK involved 80 patients with mild to
moderate AD (Bayer et al., 2005). The primary aim here was to
determine the efficacy and safety of full-length Ab1–42 peptide
with QS21. Multiple doses were tested and it was demonstrated
that 53% of patients could mount an anti-Ab humoral response.
In the later segment of the phase I trial, polysorbate 80,
which acts as an emulsifier, was added to increase the solubility
of Ab1–42. The increased emulsifier concentration caused a
greater shift from a Th2 humoral response to a proinflammatory
Th1 response (Pride et al., 2008).
A follow-up phase IIa trial was conducted in October 2001
and involved 372 patients; 300 of 372 enrolled patients were
part of the arm that received a higher formulation of QS21
(aggregated Ab1–42 with QS21 in the polysorbate 80 formula-
tion [AN1792 to placebo ratio of 4:1]. As 6% of immunized pa-
tients developed symptoms of aseptic meningoencephalitis
(18 of 298 subjects with no placebo patients developing this
complication), the trial was concluded early in January 2002
(Boche and Nicoll, 2008; Wisniewski, 2005; Wisniewski and
Frangione, 2005). The spectrum of onset of symptoms, which
included confusion, lethargy, and headache, ranged from 5 to
168 days after the last immunization the patient had received.
Neuroimaging revealed white matter lesions with or without
evidence of brain edema, termed amyloid-related imaging ab-
normalities (ARIAs). Consistent with data from animal models,
post-mortem analyses in a sub-group of trial patients revealed
apparent dramatic clearance of plaques in the brain paren-
chyma, thus validating the efficacy of this approach for precip-
itated amyloid fibril clearance in humans (Boche and Nicoll,
2008; Bombois et al., 2007; Ferrer et al., 2004; Masliah et al.,
2005a; Nicoll et al., 2003, 2006). Histopathology revealed that
there were broad stretches of cerebral cortex devoid of plaques,
interspersed with areas that had residual plaques. These persis-
tent plaques had a ‘‘moth-eaten’’ appearance or seemed to
have a ‘‘naked’’ dense core. Additionally, these plaques were
seen along with microglia that were immunoreactive for Ab, sug-
gesting that amyloid clearance here was in association with
phagocytosis. Other notable features included the presence of
unchanged tau-reactive NFTs and the persistence of amyloid
in cerebral vessels, as well as neuropil threads in apparent
regions of plaque clearing, suggesting that this preliminary
approach had not targeted vascular amyloid- or tau-related
pathology (Masliah et al., 2005a; Nicoll et al., 2006). In some pla-
ques, a T cell reaction surrounding some cerebral vessels was
observed, reminiscent of an overstimulated deleterious Th-1
immune response. These features suggested that the immune
response seemed to be working as a double-edged sword,
and raised the concern that the potential beneficial effects of
the vaccine were being counterbalanced by a deleterious
auto-toxic T cell response (Boche and Nicoll, 2008; Sadowski
and Wisniewski, 2007).
Further support in favor of a toxic response came from in vitro
studies, where peripheral blood mononuclear cells from patients
in the trial were analyzed after stimulation with the Ab peptide.
Quantification of cytokines by enzyme-linked immunosorbent
spot assays revealed that cells of responder patients could
generate IL-2- and IFN-g-positive responses, suggestive of aNeuron 85, March 18, 2015 ª2015 Elsevier Inc. 1165
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follow-up results from the Zurich cohort, a subgroup of the
Elan/Wyeth trial (Hock et al., 2002, 2003), indicated that immuni-
zation as a strategy might be beneficial for some AD patients. In
accordancewith the data from the Zurich cohort, the results from
a multi-center cohort demonstrated that people with high anti-
body titers or immune responders performed better in outcome
measures that scored memory functions relative to low- and
non-responders or to the placebo group of patients (Pride
et al., 2008). Though the pathology results with dramatic clear-
ance of plaque burden have been striking, the benefits observed
clinically in cognitive function have been very minimal (Gilman
et al., 2005). No change in function was noted between the anti-
body responders and the placebo groupwhen assessed viamul-
tiple neuropsychological rating scales. One possibility is that the
timing of intervention was incorrect. Thus, there were no effects
on NFT pathology with subsequentmild benefits in cognitive def-
icits. Furthermore, reducing the plaque burden may be inconse-
quential in the presence of existing widespread neuronal death
and dysfunction that is related more directly to toxic oligomeric
species of both Ab and tau. Another explanation is that this
approach does not target the complete pathology of AD and
other factors driving cognitive dysfunction are not addressed.
Thus, the amyloid hypothesis might be an oversimplification of
the pathogenesis of sporadic AD.
A number of next-generation Ab vaccination trials in either
Phase I or II (http://www.clinicaltrials.gov) are currently ongoing
(Table 1). Novartis Pharmaceuticals launched a Phase I trial with
an active vaccine called CAD106 (Winblad et al., 2012; Wisniew-
ski, 2012). The vaccineCAD106 is designed to target only a B cell
epitope, the small amino-terminal Ab fragment (Ab1–6), in this
case along with an adjuvant carrier that is derived from multiple
copies of the coat protein of bacteriophage Qb. Mild tomoderate
probable AD subjects with Mini Mental State Examination
(MMSE) scores ranging from 16 to 26 were enrolled in the trial.
They were randomized to two cohorts, the first that received
three injections of 50 mg CAD106 (24 test and 7 placebo sub-
jects, cohort 1) or a second cohort that received 150 mg
CAD106 (22 test and 5 placebo subjects, cohort 2). With a treat-
ment time span of 1 year and a 2-year follow-up period, the study
revealed that 75% and 100% patients developed anti-Ab IgM
titers in cohorts 1 and 2, respectively, while 67% and 82%devel-
oped anti-Ab IgG titers, respectively, in cohorts 1 and 2. Nine pa-
tients reported serious adverse reactions, but nonewere thought
to be secondary to the immunogen. In support of this idea, no
cases of meningitis, meningoencephalitis, or vasogenic edema
were identified clinically or by imaging during the initial trial or
2-year follow-up period. No significant change in cerebrospinal
fluid (CSF) biomarkers was noted in the CAD106 subjects. How-
ever, some differences were seen in cohort 2 subjects compared
to controls for plasma Ab1–40. A limitation of this trial was that it
was not sufficiently powered to demonstrate a significant clinical
difference between the treatment and control arms. The results
from the Phase II CAD106 trial, which was completed in February
2013, are yet to be reported.
Another ongoing active Phase II immunization trial, being con-
ducted by Janssen and Pfizer, is ACC-001, which uses the same
Ab(1–6) fragment coupled to a carrier protein and the surface-1166 Neuron 85, March 18, 2015 ª2015 Elsevier Inc.active saponin adjuvant QS-21 (Ryan and Grundman, 2009).
Further, Affiris AG together with GlaxoSmithKline (GSK) has uti-
lized AFFITOME(R) technology to generate synthetic antigenic
peptides called mimotopes to target the unmodified Ab N termi-
nus in their AD02 trials (Schneeberger et al., 2009). Affiris AG also
has started another Phase I trial with the same technology to
target a pyroglutamic-3-modified Ab N terminus, a post-transla-
tional modified version of Ab. This post-translational modifica-
tion of Ab that renders it more prone to aggregation is believed
to happen after its deposition in plaques or vascular amyloid
(Frost et al., 2013; Saido et al., 1995). Interestingly, pyrogluta-
mic-3-modified Ab, which is normally present in plaques and
vascular amyloid deposits but is not detectable in the CSF or
plasma, is only found in these biological fluids during therapeutic
interventions where deposited Ab has beenmobilized (DeMattos
et al., 2012). AC Immune has initiated Phase I/IIa trials with their
product, ACI-24, which works by generating a humoral immune
response to Ab in a primarily b sheet conformation. The design is
based on previous work by this group in an AD Tg model, where
a tetra-palmitoylated amyloid 1–15 peptide that exists chiefly in a
b sheet conformation was used as an immunogen (Hickman
et al., 2011; Muhs et al., 2007). The preliminary results from these
ongoing active immunization trials have yet to be reported.
These second-generation active immunization strategies were
designed to more specifically target pathological conformers of
Ab that hopefully decrease chances of autoimmune toxicity.
However, as the immunogens are still derived from the Ab
sequence, some element of cross-reactivity to normal Ab pep-
tides is to be expected, with the plausible risk of inflammatory
toxicity. Moreover, none of these approaches directly addresses
tau-related pathology.
The Past Passive Immunization Experience for AD
The process of injecting pre-made antibodies to provide host
immunity is known as passive immunization. This is in contrast
to the process of stimulating the host immune system with
agents like pre-formed antigen, a process that is called as active
immunization (Figure 2). One of the easiest ways to provide anti-
Ab antibodies without increasing the chances of uncontrolled
Th-1-mediated antibody is passive transfer of exogenous mono-
clonal anti-Ab antibodies. Importantly, studies have shown that
AD Tg model mice treated by this method developed signifi-
cantly reduced Ab level and showed cognitive benefit (Bard
et al., 2000; DeMattos et al., 2001). Passive immunization has
been associated with problems like difficulty in selection of
appropriate antigen targets, expensive costs, need for repeated
injections in chronic diseases, blood-brain-barrier (BBB) pene-
tration, hemorrhagic risk, and the triggering of immune response
to the antibodies that are injected.
Interestingly, studies have shown a number of possible
congruent mechanisms of action, which can benefit AD pathol-
ogy (Farlow and Brosch, 2013; Lemere, 2013; Moreth et al.,
2013). Anti-Ab antibodies can lead to direct Ab disassembly by
targeting Ab deposits in the brain. Microglial activation by
antibodies in the brain also can target plaques and clear
them. In addition, blockage of Ab toxicity or sequestration of
Ab monomers by antibodies prevents their aggregation in the
CNS. The ‘‘peripheral sink effect’’ has been proposed as an
Table 1. Active and Passive Trials for Immunotherapeutical Approaches to Treat AD
Pharmaceutical Company Trial Stage Status
ACTIVE
Ab Target
ELAN AN1792 Phase II (2000–2002) halted, no
improvement, encephalitis 6%
Aggregated Ab1–42, QS21,
Polysorbate80
Novartis CAD106 Phase I Ab titers, no change
biomarkers
Ab1–6/Bacteriophage Qb
Phase II Not reported
Janssen/Pfizer ACC-001 Phase II Not reported, finishing Ab1–6-QS21
Affinis AG/GSK AFFITOME AD02 Phase II Not reported Mimotope of unmodified Ab N
terminus
Affinis AG AFFITOME Phase I Ongoing Mimotope of pyroglutamic-3
modified Ab N terminus
AC Immune ACI-24 Phase I/IIa Not reported b-sheet conformation of Ab
peptide
Tau Target
Axon AAD vac1 Phase I Ongoing continuation,
tolerable, safe, antibody titers
Synthetic mutant tau peptide
coupled to KLH-ALUM
PASSIVE
Monoclonal Antibody/Target
Janssen/Pfizer Bapineuzumab
AAB-001
Phase II No clinical improvement, ARIA,
trend to efficacy
Humanized 3D6, anti-Ab1–5,
six infusions, different dosages
Phase III No improvement, halted
Eli Lilly Solaneuzumab Phase III(2) No improvement overall,
secondary analysis slight
improvement in early AD;
ongoing extension in early AD
Humanized mAb266 Anti-
Ab16–24
Janssen/Pfizer Bapineuzumab AAB-003 Phase I Ongoing Hu IgG4 3D6 to reduce ARIA
Hoffman-La Roche Gantenerumab DIAN Phase III Ongoing, future: in autosomal
dominant AD
Antibody to fibrillar form of Ab.
Positions 3–12; 18-27
Eli Lilly Solaneuzumab A4 Phase III Starting: asymptomatic AD
with positive PET
Humanized mAb266. Anti-
Ab16–24
AC Immune/Genentech Crenezumab Phase II/III Hu IgG4 anti-multiple epitopes
Ab1–40
ABBY Phase II Failed to meet clinical co-
primary endpoints
BLAZE Phase II No difference in biomarkers/
FDG-PET
API Phase III Ongoing in EOAD families with
PS1 mut. E280A
Octapharma IVIG Octapharma Phase II Safe, no improvement Three different doses of
naturally occurring anti-Ab
Baxter IVIG Gammagrad Phase III No improvement, data not
released
Naturally occurring anti-Ab
Baxter IVIG newGAM Phase II Ongoing Naturally occurring anti-Ab
Source: http://www.clinicaltrials.gov.
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deposition, namely by binding sAb circulating in the blood
stream and reducing free sAb levels, leading to sAb being drawn
out for the brain. Additional studies are needed in this area for
understanding which of these mechanisms is/are the most
important in the transgenic AD mouse model, or in the more
limited human trials.At present, several passive immunization trials are under
study. Recently reported trials of both Bapineuzumab and
Solanezumab are the two most advanced phase III trials in
this field; unfortunately, both failed to show overall clinical
improvement or any clear disease-modifying results (Doody
et al., 2014; Salloway et al., 2014). Bapineuzumab is a human-
ized version of the mouse mAb 3D6, which has an epitope ofNeuron 85, March 18, 2015 ª2015 Elsevier Inc. 1167
Figure 2. Different Immunotherapeutic Approaches to Ameliorate AD Pathology
(A) Active immunization can be performed using Ab peptides, phosphorylated tau (ptau) peptides, or preparations such as pBri as an immunogen. These im-
munogens are presented to B cells by antigen-presenting cells (APC). Use of Ab peptides or ptau peptides will give rise to the production by B cells of antibodies
to Ab or ptau epitopes, respectively. Use of pBri (or equivalent preparations of an immunogen that is a non-self peptide, in a stabilized, oligomeric b sheet
conformation) will lead to the production of antibodies that recognize both Ab and tau pathological conformers (but not normal monomeric sAb or tau proteins).
(B) Passive immunization can be performed by the production of mAbs that bind to Ab, ptau, or b sheet pathological conformations. These antibodies need to be
infused systemically in concentrations sufficient for adequate BBB penetration (typically only 0.1% of a systemically injected mAb will cross the BBB).
Once antibodies cross the BBB (using either active or passive immunization), they will act to enhance the clearance and degradation of their targets. Additional or
alternative mechanisms may include disaggregation or neutralization of their target (i.e., blocking of toxicity). Antibodies to Ab will recognize normal sAb, olig-
omeric Ab, and/or deposited fibrillar Ab (with varying preference depending on the type[s] of antibodies to Ab). Similarly, antibodies to ptau will recognize
monomeric ptau species, oligomeric tau, and/or NFTs, with varying preference depending on the specific anti-ptau antibody(ies). Antibodies to b sheet will
simultaneously act to ameliorate both Ab and tau pathologies by specifically binding pathological conformers, without binding to normal sAb or tau.
(C) Stimulation of innate immunity also can be used to ameliorate AD pathology by enhancing microglia/macrophage function via TLRs or related pathways.
Microglia/macrophages are stimulated similarly by the immune complexes produced using active or passive immunization approaches.
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Reviewresidues 1–5 of Ab. 3D6 is known to cross the BBB, and, in Tg
mouse studies, it was shown to bind plaques in the brain and
elicit Fc-receptor-mediated, microglial phagocytosis of Ab pla-
ques (Bard et al., 2000, 2003). The Phase II trials of Bapineu-
zumab (study 201 with 234 patients and study 202 with 28
patients) involved six infusions that were done every 13 weeks
at four different doses (0.15, 0.5, 1, and 2 mg/kg) (Farlow and
Brosch, 2013; Salloway et al., 2009). Even though these trials
have not showed statistically significant results overall, a post
hoc analysis restricted to subjects who received all infusions
showed significant improvement in the pooled treated group
compared to controls on the Disability Assessment of Demen-
tia (DAD) and the Alzheimer’s Disease Assessment Scale-
Cognitive subscale (ADAS-cog) (Salloway et al., 2009). In addi-
tion, among non-apoE4 carrier patients significant (but small)
benefits were documented on the ADAS-cog, Neuropsycho-
logical Test Battery (NTB), MMSE, and Clinical Dementia Rat-1168 Neuron 85, March 18, 2015 ª2015 Elsevier Inc.ing (CDR) scales. The Bapineuzumab-treated subjects showed
a reduction in cortical fibrillar amyloid deposits compared to
both baseline measures and controls over the 78 weeks of
the trial, as evaluated by 11C-PiB positron emission tomogra-
phy (PET) imaging in a subset of participants (Rinne et al.,
2010).
Some of the noteworthy complications in these trials were
related to ARIA (Sperling et al., 2012). The abnormalities
included the fluid-attenuated inversion recovery (FLAIR) MRI
signal abnormalities due to parenchymal vasogenic edema and
sulcal effusions (ARIA-E) and MRI abnormalities due to microhe-
morrhages and hemosiderosis as seen on the T2*-weighted
gradient echo (ARIA-H). Though 36 patients (17% of total pa-
tients) developed ARIA-E during treatment, it was symptomatic
only in 8 of these 36 patients (22% of patients with ARIA-E).
Adverse events included headache, confusion, neuropsychi-
atric, and gastrointestinal symptoms. ARIA-H occurred in 17
Neuron
Reviewpatients with ARIA-E and in 7 of 177 patients without ARIA-E
(Sperling et al., 2012). An association of these side effects was
seen with both the increased dose and the presence of apoE4
allele. Of eight symptomatic patients, seven were apoE4 carriers
and six were treated with the two highest doses of Bapineuzu-
mab. A possible mechanism for these adverse events is increase
in BBB permeability and microhemorrhages, due to removal of
cerebral vessel Ab (Farlow and Brosch, 2013; Sperling et al.,
2012). A higher CAA burden has been characterized previously
in apoE4 carriers (Potter and Wisniewski, 2012). On the basis
of these Phase II results, the Phase III trials were created, with
the aim of giving a lower dose (0.5 mg/kg limit) to apoE4 carriers
and to restrict the maximum dose in apoE4 non-carriers to
1.0 mg/kg. A total of 1,121 patients were involved in this phase
III trial, and infusions were given every 13 weeks for a total of
six infusions in 1.5 years. No clinical improvement was noted in
either the apoE4 carrier or non-carrier groups. In 15% of the
apoE4 group ARIA occurred, while in apoE4 non-carrier groups,
occurrences were 9% and 4% of the 1.0 mg/kg and 0.5 mg/kg
categories, respectively. In light of these observations, the clin-
ical development of Bapineuzumab has been halted. However,
AAB-003, a humanized version of Bapineuzumab (3D6) that
has mutations in the Fc domain to reduce effector function and
reduce ARIA, is in two Phase I clinical trials (http://www.
clinicaltrials.gov).
A humanized version of mAb 266, known as Solanezumab,
which has an epitope at residues 16–24 of Ab, is also under
study. In Tg mouse models, 266 was shown to bind specifically
with monomeric sAb, thereby lowering amyloid pathology while
increasing total sAb levels in the plasma (Bard et al., 2000,
2003). A reduction of free circulating sAb and Ab sequestration
in the CNS are proposed as the major mechanisms of action. A
total of roughly 800 AD patients with mild to moderate disease,
in both control and treated groups, have been followed in two
Phase III trials. The treatment group was given 400 mg of Sola-
nezumab (5.7 mg/kg) every 4 weeks. Cognition was studied
at 80 weeks and no differences were noted compared to con-
trols. When patients with mild AD were studied separately, a
small but statistically significant benefit was noted in the cogni-
tive scores (Doody et al., 2014; Farlow and Brosch, 2013). Im-
portantly, even though a high dose of Solanezumab was used
(compared to Bapineuzumab), ARIAs were not found as a
complication and an increase in plasma Ab was found (Farlow
et al., 2012). Inspired by these results, Solanezumab will be
used in two preventive or very early treatment trials. The Domi-
nantly Inherited Alzheimer Network (DIAN) trial will target adult
children in families with known mutations and a diagnosis of
FAD, as well as utilize Gantenerumab, a mAb that selectively
binds fibrillar Ab and is in an ongoing Phase III prevention trial,
involving 770 patients that lack clinical AD symptoms but on
PET scan have appreciable amyloid disease (Bohrmann et al.,
2012). Another significant prevention trial aiming to test Solane-
zumab is the A4 (Anti-Amyloid Treatment for Asymptomatic Alz-
heimer’s Disease), which includes 1,000 patients that lack
symptoms of AD but are positive for amyloid on PET scan.
The Alzheimer’s Prevention Initiative (API) is a prevention trial
to be performed in 300 people of a Colombian kindred with
PS1 mutation (E280A). A very severe AD phenotype is seen inthis mutation, characterized by Ab deposition from 25 years.
The study aims to test patients 30 years and older using Gene-
tech’s Crenezumab mAb. This antibody interacts with multiple
species of Ab (Adolfsson et al., 2012). The effector function of
Crenezumab is reduced by using a IgG4 backbone.
Another avenue of active research in passive immunization
trials is the role of intravenous immunoglobulin (IVIg) in AD. The
basis for its use is that IVIg, obtained from a large cohort of do-
nors, contains a small but significant amount of naturally acting
anti-Ab antibodies. In a number of autoimmune neurological dis-
orders, IVIg is used as an immunosuppressant and, even with
multiple successive doses, has no major side effects. Remark-
ably, a decreased risk of developing dementia is seen in patients
who receive regular IVIg infusions (Fillit et al., 2009). In a phase I,
open-label study in eight mild AD patients, IVIg was infused over
6 months, followed by an interruption, and then resumed for
another 9 months (Relkin et al., 2009). Following each infusion,
the plasma Ab levels increased transiently, with CSF Ab being
decreased after 6 months. Moreover, the MMSE increased after
6 months by an average of 2.5, and returned to baseline level af-
ter washout. A total of 23 AD biomarkers were studied in these
patients by collecting CSF from spinal taps before the initiation
of therapy, 6 months afterward, and after 3-month washout. Of
eight study subjects, significant improvement in biomarkers
was seen in six subjects after 6 months of therapy, which grad-
ually returned to baseline levels after IVIg washout (Shayan et al.,
2012). Nonetheless, in two recent trials, no significant slowing of
AD progression could be documented (Dodel et al., 2013; Le-
mere, 2013). In the Octapharma IVIg trial with 60 mild to mod-
erate AD patients, infusions were done over 6 months at three
different doses. Study methodologies such as MRI volume mea-
surement, FDG-PET, or cognitive measures did not show any
significant improvement. Of the 43 IVIg-treated patients, six
had new asymptomatic microhemorrhages. Studies by Baxter
Healthcare Corporation included an 18-month phase III trial of
Gammagrad 10% IVIg in 400 AD patients with mild to moder-
ate disease. The results from this trial have not been fully
released, but so far no significant improvement in cognitive mea-
sures has been detected (Lemere, 2013).
The passive immunization approaches that have been
described above might lack an essential element that is the
ability to specifically target Ab oligomers, which are the most
deleterious components of Ab. The prior approaches target
either both the normal and pathological conformers of Ab or
only the sAb (i.e., Solanezumab) (Panza et al., 2012). The lack
of specificity to toxic forms is a major setback in these therapeu-
tic approaches, as targeting normal sAb can interfere with its
crucial physiological functions like neuroprotection, modulation
of long-term potentiation, and innate immunity. This also may in-
crease the risk of autoimmune complications (Giuffrida et al.,
2009; Puzzo et al., 2008; Soscia et al., 2010; Wisniewski and
Gon˜i, 2014). The apparent transient effects of these therapies
also implies the need for a large number of administrations
with a tremendous burden on health care systems and the
increased risk of developing an immune response to the infused
immunoglobulins. Another crucial aspect is that these therapies
may have to be started very early in AD pathology buildup
for them to be therapeutically beneficial. Prior studies haveNeuron 85, March 18, 2015 ª2015 Elsevier Inc. 1169
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AD corresponds to peak Ab deposition, along with substantial
NFT formation and neuronal loss, which have still not yet reached
peak levels (Nelson et al., 2012; Yoshiyama et al., 2013). It is
postulated that to have a significant effect, amyloid-directed
therapy targeting sAb alone, or both the sAb and deposited Ab,
should be started early, preferably even before cognitive impair-
ment starts. It can be safely said that, as of now, these therapeu-
tic approaches have limited utility in symptomatic AD.
Tau-Related Pathology as an Immune Target
NFTs, a pathognomonic feature of AD, are intracellular inclusion
bodies that consist of deposits of paired helical filaments
(PHFs), which are primarily composed of hyperphosphorylated
tau. Recently, there has been considerable interest in targeting
phosphorylated tau for immunomodulation in AD (Boutajangout
and Wisniewski, 2014; Kayed and Jackson, 2009; Noble et al.,
2009; Sigurdsson, 2008; Yoshiyama et al., 2013). Some work
has shown that tau pathology precedes formation of amyloid pla-
ques, appearing first in the locus coeruleus and then spreading to
other brain stem nuclei and the entorhinal cortex (Braak and Del
Tredici, 2011; Elobeid et al., 2012; Jack et al., 2013). In addition,
work bymultiple groups has shown that the degree of tau-related
pathology is better correlated with the degree of dementia when
compared to the amyloid plaque burden, making tau a desirable
target in symptomaticADpatients (Arriagadaetal., 1992;Bancher
et al., 1993; Terry, 1996). Further support for this idea is provided
by the results from the human immunization trials (as reviewed
above), where the reduction in amyloid plaque load did not pro-
duce cognitive benefits in symptomatic AD subjects.
In animal models, treatment with a phospho-tau peptide (con-
taining the phosphorylated PHF-1 epitopes Ser 396 and Ser 404)
given prior to the onset of pathology was able to prevent devel-
opment of tau aggregates in the Tg P301L mouse tau model
(Asuni et al., 2007). Phosphorylation at these specific epitopes
has been shown to increase the fibrillogenic character of tau
and enhances PHF formation (Eidenmu¨ller et al., 2001; Fath
et al., 2002). This model develops NFTs in several brain regions
and the spinal cord. Two groups were immunized from 2 to
5 months and from 2 to 8 months. Immunohistochemical anal-
ysis using PHF-1 and MC1 antibodies showed a significant
reduction in tau-related pathology compared to controls. In
addition, an amelioration in the vaccinated groups was seen on
a number of sensorimotor tasks. Antibodies generated by this
vaccination were found to cross the BBB, bind to phosphory-
lated tau, and reduce pathology without significant adverse ef-
fect, thus providing strong support in favor of the idea that it is
possible to reduce tau-related pathology with active immuniza-
tion (Asuni et al., 2007). These results were confirmed in a similar
study done in an htau/PS1 tau pathology model (Boutajangout
et al., 2010). As the transgenicmice used in these studies had se-
vere locomotor deficits, a major limitation of this work was that
cognition could not be assessed as a therapeutic endpoint.
How an antibody response to a protein that has intracellular in-
clusions could have beneficial effects can be initially difficult to
understand. However, support for this idea is lent from immuni-
zation studies done in a transgenic mouse model of Parkinson’s
disease where a reduction in intracellular a-synuclein aggre-1170 Neuron 85, March 18, 2015 ª2015 Elsevier Inc.gates was demonstrated (Masliah et al., 2005b). Studies done
recently by multiple groups have suggested that anti-tau anti-
bodies can cross the BBB, and are translocated inside neurons
via low-affinity Fc receptors where they can bind to pathological
tau within the endosomal/lysosomal system (Congdon et al.,
2013). Additionally, injection of fibrillar tau brain extract into the
brains of transgenic wild-type tau-expressing mice can push
the induction of tau into filaments, along with the spread of pa-
thology from the injection site into adjacent brain regions (Clav-
aguera et al., 2009). Such an ‘‘infectivity’’ of abnormal protein
conformation from outside the cell also has been established
for polyglutamine aggregates (Ren et al., 2009) and is well
described in prion disease (Colby and Prusiner, 2011). Hence,
one can reason that, if certain pathological forms of tau can
spread and lead to PHF pathology in AD via a ‘‘prion-like’’ repli-
cativemechanism, anti-phosphorylated tau antibodiesmight not
necessarily need to enter cells to be effective.
With active immunization using tau epitopes, there exists a risk
of inducing encephalitis or neuronal apoptosis. This line of
thought is backed by an early study, where immunization of fe-
male C57BL/6 mice with full-length recombinant tau produced
neurological deficits, NFT-like changes, gliosis, and an inflam-
matory infiltrate (Rosenmann et al., 2006). Even with phosphory-
lated tau as an epitope, the possibility of deleterious effects still
persists. This risk is evident in a study where E257T/P301S-tau
Tg mice and wild-type mice were repetitively immunized with a
mixture of three phospho-tau peptides, producing neuroinflam-
mation in conjunction with significant neurological disability in
the tau Tg mice (Rozenstein-Tsalkovich et al., 2013). Hence,
one might speculate that a passive immunization approach
with anti-phospho-tau-directed mAbs might be safer. Two trials
have been conducted where passive immunization was chosen
as the targeting strategy, and revealed that tau-related pathol-
ogy andmotor deficits were reduced if the timing of the antibody
administration was prior to the onset of tau pathology (Bouta-
jangout et al., 2011; Chai et al., 2011). Another study, with serial
intracerebroventricular administration of anti-tau antibodies
(starting at 6 months of age over a 3-month period), demon-
strated a decrease in pathology and contextual fear-conditioning
deficits in P301S tau Tg mice (Yanamandra et al., 2013). Even
though this study demonstrated that administration of anti-tau
antibodies at a point when pathology is already present could
improve behavior, the intraventricular route used in this case is
a major disadvantage. Further, the only study to date to show
improvement in pathology after its onset has been unable to
show any benefits on animal survival compared to controls
(d’Abramo et al., 2013). In this report, the authors compared
DA31 (a pan-tau antibody), PHF1 (detects pSer396/404), and
MC1 (detects a pathological tau conformation) in P301L Tg tau
mice, which have an onset of pathology at about 3 months of
age. Mice injected with MC1 revealed a reduction of tau-related
pathology immunohistochemically and biochemically from 7 to
10 months. However, there was no change in survival between
mice injected with either PHF1 or MC1 from 6 to 14 months of
age versus control Tg mice (d’Abramo et al., 2013). Previously,
it had been shown that PHF1 is able to decrease tau-related pa-
thology when treatment is started prior to the onset of disease
(Boutajangout et al., 2011). Together, these results suggest
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ise, there is some risk of toxicity. For best results, more work
needs to be done to clearly define the tau form to be used and
the optimal timing of the directed immunotherapy.
Innate Immunity Stimulation as a Means to Ameliorate
AD Pathology
Studies conducted over 20 years ago had suggested the poten-
tial critical role of microglia for both the formation and clearance
of amyloid lesions in AD (Frackowiak et al., 1992; Wisniewski
et al., 1992; Wisniewski andWegiel, 1994). The importance of in-
flammatory pathways affecting the function of microglia for the
pathogenesis of AD is highlighted by the results of GWAS, where
many of the implicated genes have amajor role in immunological
processes, as well as the recent linkage to AD of a rare variant of
TREM2, a gene that regulates phagocytosis and the activation
state of microglia/macrophages (Boutajangout and Wisniewski,
2013; Karch et al., 2014).Microglia play a critical role in the innate
immune system of the CNS, and one of the most potent ways to
stimulate this system is via the Toll-like receptors (TLRs). Neuro-
inflammation can contribute to cognitive impairment and play a
significant role in AD progression (Lampron et al., 2013; Lee
et al., 2013); however, it is increasingly recognized that tightly
regulated stimulation of innate immunity processes and specific
microglia activation can be neuroprotective, depending on the
stimulus and the environment (Schwartz et al., 2013).
Microglia lose their Ab-clearing capabilities as AD progresses
(Fiala et al., 2005; Lai and McLaurin, 2012; Majumdar et al.,
2007). Senescence of microglia function has been suggested to
play a fundamental role in both AD and other neurodegenerative
diseases (Streit and Xue, 2014). Modulation of innate immunity
via TLR2, 4, and 9 signaling pathways previously has been shown
to be critical in modulating Ab deposition. TLR4-deficient mice
displayed increases of diffuse Ab and fibrillar Ab deposits com-
pared with control mice (Tahara et al., 2006), suggesting that
TLR4 signaling is involved in Ab clearance (Jin et al., 2008).Micro-
glia deficient in TLR2, TLR4, or the co-receptor CD14 are not
activated by Ab and do not show a phagocytic response (Reed-
Geaghan et al., 2009). Furthermore, stimulation of microglial cells
with TLR2-, TLR4-, or TLR9-specific agonists accelerates Ab
clearance both in vitro and in vivo (Michaud et al., 2013). It has
been shown that the administration of the TLR9 agonist CpG oli-
gonucleotides (ODN) containing unmethylated CpG sequences
to AD model Tg2576 mice induced a reduction of cortical and
vascular Ab levels,without apparent toxicity, and improvedcogni-
tive function, with a recent study in 3xTg mice showing the same
approach also can reduce tau-related pathology in association
with cognitive benefits (Scholtzova et al., 2009, 2014). Various
CpG DNA drugs that are TLR9 agonists have been shown to be
safe for both humans and rodents (Vollmer and Krieg, 2009).
Hence, these preclinical studies indicate that modification of mi-
croglial function in neurodegeneration is a viable therapeutic
target to ameliorate both Ab and tau pathologies.
Targeting Abnormal Protein Conformation Rather Than
Ab- or Tau-Related Pathology Individually
The most pathological conformers of Ab and aggregated tau
have been proposed to be oligomeric. Both of these entitieshave been demonstrated to be soluble, very mobile forms that
spread extracellularly using prion-like replicative mechanisms.
Notably, recent studies have shown that, in the presence of Ab
amyloid pathology, therapeutic interventions that impede Ab
oligomer toxicity can reverse cognitive deficits within a remark-
ably short treatment duration (Barry et al., 2011; Chung et al.,
2010). It can be safely concluded that these molecular targets
have great potential even when significant pathology is present.
A number of structural and biophysical properties are shared
between Ab and tau oligomers, like a high b sheet content,
neuronal toxicity, and imperviousness to proteolytic degrada-
tion. A limited number of studies using antibodies that specif-
ically target Ab oligomers reflect the potentially powerful role of
this approach and warrant further attention (Lambert et al.,
2007, 2009; Lee et al., 2006; Mamikonyan et al., 2007; Moretto
et al., 2007; Rasool et al., 2013). Another benefit of targeting
only the oligomeric form of Ab or tau is that the normal physiolog-
ical function of these proteins remains intact. A recently pro-
posed approach used conformationally specific antibodies or
active immunization that aimed to target the shared abnormal
b sheet confirmation of amyloid proteins (Lee et al., 2006; Mor-
etto et al., 2007; Wisniewski et al., 2009). This approach has
the benefit of simultaneously targeting both the Ab- and tau-
related pathologies.
Our group has been actively engaged in this approach for the
last several years (Wisniewski and Gon˜i, 2014). To accomplish
this goal, we developed a therapeutic immunomodulation, spe-
cific for pathological b sheet conformation, shared by Ab and
tau disease-associated species. In our studies, we employed a
polymerized peptide derived from the carboxyl terminus of the
British amyloidosis (ABri) peptide prepared by the use of glutar-
aldehyde as a cross-linker, which results in a stabilized, predom-
inately b sheet oligomeric form that does not form fibrils and that
we term pBri (Gon˜i et al., 2010, 2013). One of the rare forms of
familial human amyloidosis is ABri, which is associated with a
missense mutation in a stop codon that leads to transcription
of an intronic sequence, thereby causing production of a highly
amyloidogenic protein with a carboxy terminus that lacks
sequence homology to Ab, tau, or any other native human pro-
teins (Rostagno et al., 2005; Vidal et al., 1999). We proposed
that, via conformational mimicry, the pBri peptide in its stabilized
oligomeric form can initiate a conformation-selective immune
response, which is specific to pathological aggregated/oligo-
meric conformers of phosphorylated tau and Ab. An immuno-
modulatory approach of such design will have a decreased risk
of causing autoimmune complications, as it is specific to patho-
logical conformers and the immunogen does not have sequence
homology to any mammalian peptide. Our past studies have
shown that this immunomodulation targeting of pathological
conformation of Ab is highly effective in reducing amyloid pla-
ques and produces cognitive rescue (Gon˜i et al., 2010). Our
recent studies have demonstrated that our approach of targeting
abnormal protein confirmation is effective in both the TgSwDI
mice, which have a high burden of vascular pathology, and in
3xTg mice, which have both Ab- and tau-related pathologies. It
decreases the disease pathology of both deposited conformers,
but most importantly the soluble oligomeric levels of Ab and tau,
leading to improvement in cognitive deficits (Gon˜i et al., 2013).Neuron 85, March 18, 2015 ª2015 Elsevier Inc. 1171
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most likely related to interfering with the intermediate oligomeric
forms of Ab and tau before they fibrillize, rather than directly
acting on the plaques and NFTs.Conclusions
It is an exciting time, with many different active and passive im-
munization therapeutic approaches currently either under devel-
opment or in trials. In addition, pre-clinical studies are exploring
innate immunity stimulation. Strategies that target Ab peptides
could be effective if used very early in disease onset, before
the development of any clinical dysfunction, and are currently
in ongoing prevention trials. Though immunotherapy targeted
toward tau pathology has shown some promise, it bears the
risk of toxicity. With the current knowledge, it remains undefined
if it can be used effectively in symptomatic ADwhere there is pre-
existing pathology. Many studies have shown that, even at the
mild cognitive impairment stage of AD, extensive amyloid and
tau pathologies are already present (Nelson et al., 2012). Also,
it has been proposed that, in sporadic LOAD, tau pathology is
not simply downstream of Ab-related pathology, but that these
pathologies could be generated by dual pathways that can
interact synergistically (Small and Duff, 2008; Yoshiyama et al.,
2013). If this holds true, it would be essential to devise an
approach that could simultaneously and effectively target both
pathologies.
We postulate that such a strategy that can harness the im-
mune system to clear both Ab and tau toxic oligomers concur-
rently might be most efficacious in symptomatic AD. This might
be possible by seeking similarities in the tau and Ab toxic con-
formers to actively induce a humoral immune response via
conformational mimicry. An active immunization approach of
the same type also can be used for the development of mAbs,
to be used alone or as a panel, possibly with other agents in
different stages of AD. This ‘‘b sheet buster’’ approach repre-
sents a unifying therapeutic methodology where pathological
protein conformation is being targeted, offering potential prom-
ise for multiple conformational neurodegenerative diseases.ACKNOWLEDGMENTS
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